The first and only genetic test to blend comprehensive assessment for hereditary cancer risk with the precision of genomic breast cancer risk assessment for patients of all ancestries
Achieving better patient outcomes requires a new approach to cancer risk assessment
Only 5% of patients with a significant family history of breast cancer have an identifiable genetic syndrome1
MyRisk with RiskScore provides a personalized genetic answer for up to 100% of eligible, unaffected patients, regardless of ancestry
Click here to receive a test kit
Included in the Myriad MyRisk Hereditary Cancer test, RiskScore delivers a personalized 5-year and remaining lifetime risk for breast cancer.
Precision beyond Tyrer-Cuzick using genomic insights
RiskScore is the only breast cancer risk assessment test that incorporates the patient’s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers.
Current eligibility for RiskScore
56% of tested women need additional care
For women tested in a preventive setting1, more than half will have a cancer risk high enough to warrant a medical management plan above what is recommended for the general population. A fraction are due to a high-risk mutation, and the majority are due to the patient’s personalized risk assessment, including RiskScore.
Myriad MyRisk Management Tool
Included with both positive and negative results, the Myriad MyRisk Management Tool details relevant societal guidelines, personalized to your patient, based on their RiskScore and family history risk assessment. The easy-to-read format to provides you and your patient clarity and confidence as you form a plan together.
Contact a Myriad Representative
In order to address this need, Myriad continues to run one of the largest Genome Wide Association Studies (GWAS) for women of African ancestry in the world.
Given that genetic markers that are linked to breast cancer in one population may not convey the same risk across ancestries, Myriad performed extensive research to ensure that genetic markers are conveying the correct level of risk for patients.
By working with the Women’s Health Initiative (WHI), Myriad collaborated on a study of over 90,000 participants to determine the performance of the Tyrer-Cuzick risk model in patients of non-European ancestry.2
Barriers prevented polygenic risk scores for breast cancer from being available for women of all ancestries. In order to offer precision breast cancer risk assessment for women of all ancestries, Myriad took steps to address some of these challenges.
At Myriad Genetics, we believe that personalized genetic tests need to be accurate and accessible for people of all ancestries. Across our portfolio of products, we are committed to providing equity in care, investing in science that benefits patients of all ancestries, and the availability of precision genetic insights for all patients.
Our mission and purpose at Myriad Genetics is to advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. It is more relevant than ever, and we are committed to fulfilling it – working together to uncover new opportunities, make health more precise and personal, and push the frontiers of what’s possible.
*Must also not have any blood relatives with a known high-risk breast cancer-related gene mutation. European or Ashkenazi Jewish patients with a CHEK2 mutation who meet other clinical eligibility criteria will receive a RiskScore.
2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.